GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » 14-Day RSI

Biomea Fusion (Biomea Fusion) 14-Day RSI : 49.84 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-05), Biomea Fusion's 14-Day RSI is 49.84.

The industry rank for Biomea Fusion's 14-Day RSI or its related term are showing as below:

BMEA's 14-Day RSI is ranked worse than
54.29% of 1575 companies
in the Biotechnology industry
Industry Median: 48.86 vs BMEA: 49.84

Competitive Comparison of Biomea Fusion's 14-Day RSI

For the Biotechnology subindustry, Biomea Fusion's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomea Fusion's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's 14-Day RSI falls into.



Biomea Fusion  (NAS:BMEA) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomea Fusion  (NAS:BMEA) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Biomea Fusion 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomea Fusion (Biomea Fusion) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Executives
Juan Pablo Frias officer: Chief Medical Officer 900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc. 10 percent owner 59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director, 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m. director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle officer: Chief Financial Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust director C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann director, 10 percent owner, officer: President and COO 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler director, 10 percent owner, officer: CEO 726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc 10 percent owner 726 MAIN STREET, REDWOOD CITY CA 94063

Biomea Fusion (Biomea Fusion) Headlines

From GuruFocus